Proprietary, high-order multiplexing methodology

MultiOmyx: proprietary, high-order multiplexing methodology

MultiOmyx enables visualization and characterization of up to 60 proteins in a single formalin fixed, paraffin embedded (FFPE) 4μm tissue section. Slides are prepared and stained using MultiOmyx multiplexing IF staining protocol. For each round of staining, conjugated fluorescent antibodies are applied to the slide, followed by image acquisition of stained slides. The dye is erased, enabling a subsequent round of staining with another pair of fluorescent antibodies.


Download the MultiOmyx Panel Brochure:
Using our broad array of verified MultiOmyx panels (TIL, TLS, etc.) in your study


MultiOmyx Immune Cell Figure

Comprehensive immunophenotyping from a single slide

Immunotherapy is a cancer treatment approach that in recent years has resulted in great clinical success. In order to develop effective precision immunotherapies, it is important to identify immune checkpoint targets and the types and locations of immune cells in the tumor microenvironment; e.g., B cells, T cells, Tumor-Associated Macrophages (TAMs), and others. MultiOmyx Tumor Infiltrating Lymphocyte Panels provide the ideal solution – quantitative analytical results from every cell on your single FFPE slide.

MultiOmyx also offers:

  • Unambiguous immune cell co-expression and co-localization
  • Advanced quantitative cellular classification
  • Medical, scientific, & bioinformatics consultation
  • Custom assay design & verification
  • Advanced image analysis & visualization tools
  • Spatial analytics
  • Integrated with FISH, RNAScope, and NGS
  • High order: >= 7-plex
  • Comprehensive analysis of tumor biology
  • Monitoring of the immune microenvironment for the characterization of tumors pre- and post- I/O treatment
  • Comprehensive Immunophenotyping at single cell level from one FFPE slide
Test Slide Requirements Requirements
MultiOmyx™ Duplicate slides per sample, cut at thickness of 3-5 microns. Transport of paraffin blocks and unstained slides are at room temperature. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.

Specimen requirements for tumor tissue: FFPE tissue: Paraffin block is preferred, slide preferences are listed above

Storage and Transportation: Use cold pack for transporting block and/or blood, making sure cold pack is not in direct contact with specimen. Peripheral Blood: Ship same day as drawn whenever possible; specimens <72 hours old.

MultiOmyx Technologies & Applications


MultiOmyx Hyperplexed Immunofluorescence Assay

Analyze Up to 60 Stains on a Single Slide

MultiOmyx™ assay has similar staining characteristics as standard immunohistochemical stains, and has the significant advantage that multiple proteins demonstrated up to 60 can be interrogated from a single FFPE section1. Direct comparison of multiple biomarkers is made on the same cell, enabling routine co-expression analysis and identification of cells requiring multiple biomarkers staining (e.g., Tregulatory CD3+CD4+FoxP3+).


MultiOmyx Hyperplexed Immunofluorescence Assay

Immune Cells

Unambiguous Classification of Immune Cell Phenotypes

MultiOmyx technology allows for direct comparison of multiple biomarkers on the same cell, enabling unambiguous classification of immune cell phenotypes to differentiate T cells, B cells, NK cells, macrophages, and dendritic cells in the tumor microenvironment. Without being restricted to a handful of markers, MultiOmyx can further differentiate functionally, activated immune cells from suppressed immune cells in context to tumor, stroma, and tumor margins.

Functional Differentiation of Tcytotoxic

Functional Differentiation of Tcytotoxic

MultiOmyx staining was performed on CD3, CD4, CD8, CD45RO, GRANZYMe B, PD1, and Ki67 to identify memory Tcytotoxic (CD3+CD4-CD8+CD45RO+), effector Tcytotoxic (CD3+CD4-CD8+Granzyme B+), anergic Tcytotoxic (CD3+CD4-CD8+PD1+) and proliferating Tcytotoxic(CD3+CD4-CD8+Ki67+) cells. Arrows indicate Tcytotoxic cells representing each of the four functional classifications in their respective images.

Latest MultiOmyx News

PAK4 as a potential marker for poor response to immunotherapy in melanoma patients

ESMO 2022
Sep 9, 2022

Spatial interrogation of tertiary lymphoid structures (TLS) in colorectal carcinoma (CRC) tumor microenvironment (TME) using the MultiOmyxTM assay

AACR 2022
Apr 14, 2022

Quantitation of CD137 and Nectin-4 expression across multiple tumor types to support indication selection for BT7480, a Bicycle TICA™

SITC 2021
Nov 13, 2021

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients